Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

New York, NY, May 8th, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member.

Huerga brings over two decades of experience at the intersection of artificial intelligence and oncology drug development. He was most recently Chief Data Scientist for Oncology R&D at AstraZeneca and formerly Executive Vice President at Tempus Labs. A repeat biotech entrepreneur, he has founded three oncology companies, with two successful exits. At Pathos, Huerga will lead the company’s next phase of growth as it scales its AI-driven platform to accelerate clinical success in oncology.

“I’m thrilled to join Pathos at this pivotal moment,” said Huerga. “We’re building the first true AI-enabled drug development platform—one that prioritizes clinical outcomes, precision in patient selection, and speed to patients. With our unique multimodal data and AI capabilities, we believe Pathos can dramatically accelerate oncology drug development and bring new life to promising compounds that have been overlooked or deprioritized.”

Under Huerga’s leadership, Pathos will expand its mission to integrate multimodal data, advanced artificial intelligence, and clinical insight into a next-generation platform for oncology innovation, accelerating the path from molecule to medicine for patients worldwide.

As part of the leadership transition, Ryan Fukushima, who served as interim CEO, will take on a new role as Advisor and remain a Board Member.

Pathos is pioneering a new model for AI-enabled drug development—one that leverages multimodal data, advanced artificial intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine.

< Older Post

Newer Post >

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

By Jeremy Fodor • August 4, 2026

NEW YORK, August 3rd, 2026 (GLOBE NEWSWIRE) — Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab. Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive license to research, develop, manufacture and commercialize JSKN016 in territories outside the Chinese Mainland, Hong Kong, Macau and Taiwan, with Pathos bearing all related development and commercialization costs and expenses under the agreement. Alphamab retains its full and exclusive rights to develop, manufacture and commercialize JSKN016 in the Chinese Mainland, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Alphamab is entitled to receive a non-refundable upfront payment of US$125 million and milestone payments based on the achievement of certain development and commercialization milestones, totaling up to US$2,093 million, as well as tiered royalties at high-single digit to low-double digit percentage rates according to aggregate annual net sales in the licensed territories.

Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

contacts

more news & insights

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC